RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases

Blood Cells, Molecules, and Diseases

Volumn 37, Issue 3, 2006, Pages 197-203

  Diaz Font, Anna ^a   Chabás, Amparo ^b   Grinberg, Daniel ^a   Vilageliu, Lluïsa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Institut de Bioquimica Clinica Barcelona   (Spain)

Author keywords

Gaucher disease; GCS UGCG gene; siRNA; Therapeutic approach

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; GENE PRODUCT; GLYCOSPHINGOLIPID; PROTEIN UGCG; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPRESSION VECTOR; FABRY DISEASE; FEMALE; GAUCHER DISEASE; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE SYNTHESIS; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; LIPIDOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATION; PLASMID; PLASMID VECTOR; PRIORITY JOURNAL; REDUCTION KINETICS; RNA INTERFERENCE;

ANIMALS; GAUCHER DISEASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HELA CELLS; HUMANS; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 33750831013     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.07.002     Document Type: Article

References (29)

1. Beutler E., Kay A., Saven A., Garver P., Thurston D., Dawson A., and Rosenbloom B. Enzyme replacement therapy for Gaucher disease. Blood 78 (1991) 1183-1189
2. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., Platt F., Butters T., Dwek R., Moyses C., Gow I., Elstein D., and Zimran A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
3. Pastores G.M., and Barnett N.L. Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin. Invest. Drugs 12 (2003) 273-281
4. Weinreb N.J., Barranger J.A., Charrow J., Grabowski G.A., Mankin H.J., and Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am. J. Hematol. 80 (2005) 223-229
5. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., and Kelly J.W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15428-15433
6. Becker P.S. The current status of gene therapy in autologous transplantation. Acta Haematol. 114 (2005) 188-197
7. Cheng S.H., and Smith A.E. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 10 (2003) 1275-1281
8. Diaz-Font A., Cormand B., Chabás A., Vilageliu L., and Grinberg D. Unsuccessful chimeraplast strategy for the correction of a mutation causing Gaucher disease. Blood Cells, Mol. Dis. 31 (2003) 183-186
9. Uprichard S.L. The therapeutic potential of RNA interference. FEBS Lett. 579 (2005) 5996-6007
10. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 (2002) 199-213
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
12. Shukla G.S., and Radin N.S. Glucosyceramide synthase of mouse kidney: further characterization with an improved assay method. Arch. Biochem. Biophys. 283 (1990) 372-378
13. Egido-Gabás M., Serrano P., Casas J., Llebaria A., and Delgado A. New aminocyclitols as modulators of glucosylceramide metabolism. Org. Biomol. Chem. 3 (2005) 1195-1201
14. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
15. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev., Drug Discov. 3 (2004) 318-329
16. Lee S.B., Rodriguez D., Rodriguez J.R., and Esteban M. The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology 231 (1997) 81-88
17. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
18. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 20 (2002) 446-448
19. Schubert S., Grunweller A., Erdmann V.A., and Kurreck J. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J. Mol. Biol. 348 (2005) 883-893
20. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., and Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21 (2003) 635-637
21. Semizarov D., Frost L., Sarthy A., Kroeger P., Halbert D.N., and Fesik S.W. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6347-6352
22. Bantounas I., Phylactou L.A., and Uney J.B. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J. Mol. Endocrinol. 33 (2004) 545-557
23. Boado R.J. RNA interference and nonviral targeted gene therapy of experimental brain cancer. NeuroRx 2 (2005) 139-150
24. Rossi J.J. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther. 13 (2006) 583-584
25. Diallo M., Arenz C., Schmitz K., Sandhoff K., and Schepers U. Long endogenous dsRNAs can induce complete gene silencing in mammalian cells and primary cultures. Oligonucleotides 13 (2003) 381-392
26. Yamashita T., Wada R., Sasaki T., Deng C., Bierfreund U., Sandhoff K., and Proia R.L. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9142-9147
27. Thakker D.R., Hoyer D., and Cryan J.F. Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol. Ther. 109 (2006) 413-438
28. Check E. A crucial test. Nat. Med. 11 (2005) 243-244
29. Whelan J. First clinical data on RNAi. Drug Discovery Today 10 (2005) 1014-1015